ContraFect Announces Several New Data Presentations

YONKERS, NY, April 18, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX)a late-stage clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysines and amurine peptides, as new medical modalities for the treatment of life-threatening and resistant infections antibiotics, today announced that the company has been selected for one oral presentation and six poster presentations at the 32n/a The annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) will take place from April 23-26, 2022 in Lisbon, Portugal. The data presented will feature exebacase, the Company’s breakthrough therapy-nominated product candidate currently being studied in a pivotal Phase 3 superiority design study, CF-370, a lysine product candidate from engineering demonstrating power in vitro bactericidal activity against resistant Gram-negative pathogens, as well as lead compounds from the Company’s proprietary amurine peptide program.

ECCMID 2022 Presentation Details:

Session: 05. New antibacterial agents, PK/PD & Stewardship
5a. Mechanisms of action, new compounds, preclinical data and pharmacology of antibacterial agents

ORAL PRESENTATION:

Title: invivo Efficacy of CF-370 Alone and in Addition to Amikacin in the Rabbit Model of Acute Pneumonia Caused by an Extremely Drug Resistant (XDR) Agent Pseudomonas aeruginosaAR-769

Speaker: Dario Lehoux, Ph.D., Head of Preclinical Development, ContraFect

Date of presentation: tuesday 26 apriland, Room G; 00819

Session time: 3:30 a.m. to 5:30 a.m. ET

Abstract ID # 00513

POSTER PRESENTATIONS:

Title: Lysine CF-370 has a low propensity to decrease susceptibility to Gram-negative pathogens (GN) ESKAPE
Available online: April 23rd-26and
Poster P1296; Abstract identifier #01724

Title: Lysin CF-370 removes in vitro resistance in Pseudomonas aeruginosa to meropenem, tobramycin and levofloxacin
Available online: April 23rd-26and
Poster P1294; Abstract identifier #01730

Title: Direct lytic agents, a new family of antimicrobial agents, have a low propensity to decrease susceptibility of Gram-negative pathogens associated with respiratory tract infection in cystic fibrosis
Available online: April 23rd-26and
Poster P1295; Abstract identifier #01727

Session 03. Bacterial sensitivity and resistance

3a. Resistance monitoring and epidemiology: MRSA, VRE and other Gram-positives

POSTER PRESENTATION:

Title: In vitro activity of exebacase against contemporary beta-hemolytic streptococci recovered from US patients with bloodstream infections

Available online: April 23rd-26and

Displays P0496; Abstract ID # 00566

Session 03. Bacterial sensitivity and resistance

3c. Susceptibility testing methods (including test validation and comparative studies, excluding Tb

POSTER PRESENTATIONS:

Title: Evaluation of the broth microdilution MIC method for exebacase against 100 beta-hemolytic streptococci

Available online: April 23rd-26and

Abstract ID #00560; Attach; P0771

Title: Exebacase MIC Reproducibility Assessment: Thirty S. aureus isolates tested at three sites using three different lots of commercial media

Available online: April 23rd-26and

Displays P0772; Abstract ID #00388

All posters will be made available to meeting registrants upon request via the ECCMID website.

After the meeting, the presentations will be available on the ContraFect website.

About ContraFect

ContraFect is a biotechnology company focused on the discovery and development of DLA, including lysines and amurine peptides, as novel medical modalities for the treatment of life-threatening, antibiotic-resistant infections. It is estimated that 700,000 deaths worldwide each year are attributed to antimicrobial resistant infections. We intend to treat life-threatening infections using our therapeutic product candidates from our DLA platform, which include lysines and amurine peptides. Lysines are a novel class of DLAs that are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with rapid killing of target bacteria, eradication of biofilms, and synergy with conventional antibiotics. Amurine peptides are a novel class of DLAs that exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumanniiand Enterobacter species. We believe that the properties of our lysines and amurine peptides will make them suitable for targeting antibiotic resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Golden Staph bacteremia, including endocarditis, with our lead lysine candidate, exebacase, which is the first lysine to enter clinical studies in the United States. MRSA bacteremias, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.

Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

Forward-looking statements

This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the United States federal securities laws. Forward-looking statements can be identified by words such as “plans”, “may”, “will”, “could”, “would”, “should”, “believe”, “expect”, “anticipate”, “estimates,” “intends,” “expects,” “potential,” “promises,” or similar references to future periods. Examples of forward-looking statements in this release include, but are not limited to, statements regarding: ECCMID presentations and data presented, ContraFect’s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening and antibiotic-resistant infections, whether ContraFect will treat life-threatening infections using therapeutic candidates from its DLA platform, whether lysines are a new class of DLAs that are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, so amurines are a novel class of DLAs that exhibit broad-spectrum activity against a wide range of drug-resistant Gram-negative pathogens. antibiotics, and whether the properties of lysines and a ContraFect murines will make them adept at targeting antibiotic-resistant bacteria organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts or guarantees of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, expected events and trends, the economy and other conditions. future. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including the occurrence of any event adverse events related to the discovery, development, and commercialization of ContraFect’s product candidates such as adverse clinical trial results, insufficient pharmaceutical supplies, lack of regulatory approval, or failure to obtain or the maintenance of patent protection and other significant risks detailed under the heading “Risk Factors” in the documents filed by ContraFect with the Commission de Sécurité et d’Échanges. Actual results may differ from those set forth in forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based solely on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligation to publicly update any forward-looking statements, written or oral, which may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contacts:

Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: [email protected]

Media:

Jules Abraham
COREIR
Tel: 917-885-7378
Email: [email protected]

About Nereida Nystrom

Check Also

Activision Blizzard’s New ‘Diversity Space Tool’ Used For CoD And Overwatch 2 Stuns Some Fans

Activision Blizzard has announced a new tool that will be used by its game developers …